A prospective, multicentre, non-interventional, observational, post-authorisation safety study of ropeginterferon alfa-2b (250 micrograms or 500 micrograms solution for injection in pre-filled pen) in adult polycythaemia vera patients
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
Most Recent Events
- 08 Jun 2023 New trial record
- 02 Jun 2023 According to AOP Health media release, this post-approval safety study (BESREMI-PASS) with a recruitment period of about three years has just completed patient recruitment.